N/A
N=32
High Flow Nasal Cannula for Obstructive Sleep Apnea
Obstructive Sleep Apnea
Bottom Line
View on ClinicalTrials.gov: NCT03843372 ↗Enrolled (actual)
32
Serious AEs
0.0%
Results posted
Dec 2020
Primary outcome: Primary: Apnea Hypopnea Index — 6.15; 14.85 events per hour — p=<0.001
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- High flow nasal cannula (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Chung-Chieh, Yu
- Primary completion
- Dec 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Apnea Hypopnea Index |
6.15; 14.85 | <0.001 sig |
| PRIMARY Oxygen Desaturation Index |
1.25; 5.25 | <0.001 sig |
| SECONDARY Total Sleep Time |
343; 292.75 | <0.001 sig |
| SECONDARY Sleep Efficiency |
86.1; 74.25 | 0.008 sig |
Summary
This study compare the efficacy of high flow nasal cannula with nasal continuous positive airway pressure. All of participants will be randomized to receive one night high flow nasal cannula therapy and another night for nasal continuous positive airway pressure.
Eligibility Criteria
Inclusion Criteria
- Apnea hypopnea index greater than 5 times per hour
- Age greater than 18 years old.
Exclusion Criteria
- Central sleep apnea
- Hypoventilation syndrome
- Chronic obstructive airway disease
- Receive soft palate surgery or used an oral appliance
- Intolerance to transnasal high flow or CPAP
- Pregnant women
- Unstable hemodynamic state
- Eastern Cooperative Oncology Group Performance Status higher than grade 2
Data sourced from ClinicalTrials.gov (NCT03843372). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.